M8046

Mifepristone

≥98%

• Sinónimos: 11β-(4-Dimethyl­amino)­phenyl-17β-hydroxy-17-(1-propynyl)­estra-4,9-dien-3-one, RU-38486, RU-486
• Fórmula empírica (notación de Hill): C₂₉H₃₅NO₂
• Número de CAS: 84371-65-3
• Peso molecular: 429.59
• Número MDL: MFCD00867226
• Código UNSPSC: 51111800
• ID de la sustancia en PubChem: 24278572
• NACRES: NA.77

Propiedades

• origen biológico: synthetic (organic)
• esterilidad: non-sterile
• Ensayo: ≥98%
• Formulario: powder
• técnicas: inhibition assay: suitable
• solubilidad: ethanol: 50 mg/mL, clear, greenish-yellow
• emisor: Danco Laboratories
• Condiciones de envío: ambient
• temp. de almacenamiento: 2-8°C
• cadena SMILES: [H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]4(C)[C@@]2([H])CC[C@@]4(O)C#CC)c5ccc(cc5)N(C)C
• InChI: 1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
• Clave InChI: VKHAHZOOUSRJNA-GCNJZUOMSA-N
• Información sobre el gen: human ... AR(367) , ESR1(2099) , ESR2(2100) , HTR1A(3350) , HTR1B(3351) , HTR1D(3352) , HTR1E(3354) , HTR1F(3355) , HTR2A(3356) , HTR2B(3357) , HTR2C(3358) , HTR3A(3359) , HTR3B(9177) , HTR3C(170572) , HTR3D(200909) , HTR3E(285242) , HTR4(3360) , HTR5A(3361) , HTR5B(645694) , HTR6(3362) , HTR7(3363) , NR3C1(2908) , NR3C2(4306) , PGR(5241) ; mouse ... Nr3c1(14815) ; rat ... Nr3c1(24413) , Tat(24813)

Descripción

Descripción general

Mifepristone, a synthetic steroid, can be utilized for the management of Cushing′s syndrome and uterine leiomyomas. At low doses, it selectively antagonizes progesterone by binding to the intracellular progesterone receptor. At higher doses, mifepristone blocks cortisol at the glucocorticoid receptor, affecting the hypothalamic-pituitary-adrenal axis and leading to increased circulating cortisol, thereby controlling hyperglycemia in some patients. Additionally, mifepristone has a higher affinity for the glucocorticoid II receptor than for the glucocorticoid I receptor. In cases of pregnancy termination, mifepristone disrupts progesterone.

Aplicación

Mifepristone has been used:

• to induce damage against the proliferative and secretory phase of endometrial stromal cells
• to establish a preterm birth (PTB) mice model in order to study the difference in cervical ripening mechanism between term and PTBs
• to activate geneswitch gal4 in flies
• to study the effects of sex steroids on prostaglandin secretion

Acciones bioquímicas o fisiológicas

Mifepristone (RU-486) has activity as both a progesterone receptor antagonist and a glucocorticoid receptor antagonist.

Therefore, mifepristone is considered to be a potent abortifacient. It is also known to inhibit human chorionic gonadotropin. Mifepristone results in decidual necrosis.

Características y beneficios

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Danco Laboratories. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Pictogramas: GHS08
• Palabra de señalización: Danger
• Frases de peligro: H360
• Consejos de prudencia: P201 - P308 + P313
• Clasificaciones de peligro: Repr. 1B
• Código de clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable
• Equipo de protección personal: Eyeshields, Gloves, type P3 (EN 143) respirator cartridges